Cargando…

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China

INTRODUCTION: Bruton tyrosine kinase inhibitor (BTKi) has demonstrated substantial efficacy in treating B-cell lymphoproliferative diseases (BLPD). Nonetheless, the significant discontinuation rates due to toxicity or financial reasons cannot be overlooked. In China, empirical evidence on the usage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Yuting, Lv, Rui, Wang, Tingyu, Yu, Ying, Huang, Yanshan, Xiong, Wenjie, Li, Yuxi, Sui, Weiwei, Wang, Qi, Huang, Wenyang, An, Gang, Zou, Dehui, Wang, Jianxiang, Qiu, Lugui, Yi, Shuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360166/ https://www.ncbi.nlm.nih.gov/pubmed/37483630 http://dx.doi.org/10.3389/fimmu.2023.1184395

Ejemplares similares

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia
por: Xiong, Wenjie, et al.
Publicado: (2023)

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders
por: Yi, Shuhua, et al.
Publicado: (2017)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
por: Yi, Shuhua, et al.
Publicado: (2020)

P1162: FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA
por: Zou, Hesong, et al.
Publicado: (2023)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
por: Xiong, Wenjie, et al.
Publicado: (2023)

Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China
por: Li, Heng, et al.
Publicado: (2017)

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
por: Cao, Tingyu, et al.
Publicado: (2022)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM
por: Wang, Jun, et al.
Publicado: (2022)

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
por: Yi, Shuhua, et al.
Publicado: (2022)

Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region
por: Yi, Shuhua, et al.
Publicado: (2017)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
por: Sun, Hao, et al.
Publicado: (2022)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
por: Liu, Jiahui, et al.
Publicado: (2023)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
por: Hao, Mu, et al.
Publicado: (2011)

Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment
por: Li, Sidan, et al.
Publicado: (2015)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ttuf36onoildvvhpo5co2md5tt